Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Substudy Supports Reduced Risk of Metastasis and Death

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide -- a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) -- plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care. The substudy, co-led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain and published today in European Urology.

October 26, 2026


November 7 2026

November 6 2026

November 5 2026

November 4 2026

November 3 2026

November 2 2026

November 1 2026

October 30 2026

October 29 2026

October 28 2026

October 27 2026

October 26 2026

October 25 2026